COVIPACT 2: Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19

Sponsor
Centre Francois Baclesse (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04747249
Collaborator
(none)
29
1
1
14.5
2

Study Details

Study Description

Brief Summary

In the context of the COVID-19 pandemic, concerns of the risk of infection may lead to fear, anxiety or psychological disorders that may become generalised and long-lasting, corresponding to post-traumatic stress disorder (PTSD). PTSD generally occurs in circumstances such as terrorist attacks, hostage-taking, bombings, aggression, accidents... The current health crisis also represents an increased risk of PTSD.

After the first moments of stress, the illness becomes more diffuse: personality change (introverted/extraverted), sleep disorders, heart problems, hypervigilance reaction, agoraphobia, symptoms of reminiscence, irritability, decreased concentration, memory loss... In some people, PTSD can lead to more disabling problems such as (crowd) avoidance.

In order to help patients with PTSD, clinical psychology offers therapeutic approaches which, starting from a debriefing with the patient, provide supportive therapy which (i) reassures by providing information on the symptomatology, in order to play down the present state of mind, (ii) allows for the expression of what was experienced during the event, (iii) initiates a process of elaboration of the trauma through transference.

A study initiated at the François Baclesse Centre during the first confinement, which included 735 patients from April to June 2020, made it possible to assess the impact of the pandemic linked to COVID-19 on the care of cancer patients treated in day hospitals, but also to evaluate the PTSD experienced by patients, sleep difficulties, quality of life, cognitive complaints and confinement conditions using validated questionnaires. This study showed that 21% of patients had proven PTSD and 23% had insomnia problem.

This study proposes to evaluate the value of adapted psychological care for patients with PTSD in relation to the pandemic on the improvement of PTSD, as well as on resilience, quality of life and sleep.

Condition or Disease Intervention/Treatment Phase
  • Other: Psychological support
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
29 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Psychological supportPsychological support
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19
Actual Study Start Date :
Jun 18, 2021
Actual Primary Completion Date :
Mar 31, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Psychological support

Monthly psychological support

Other: Psychological support
Psychological care will be based on a monthly interview lasting approximately 45 minutes for 6 months.

Outcome Measures

Primary Outcome Measures

  1. Proportion of patients with improvement in post-traumatic stress symptoms [6 months]

Secondary Outcome Measures

  1. Resilience Scores [6 months]

    Done with Connor-Davidson Resiliency Scale

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient ≥ 18 years old

  • Patient treated or followed up for a solid tumour at the François Baclesse Centre

  • Patient with a score suggesting moderate or high posttraumatic stress symptoms (IES-R score ≥ 24) related to the COVID-19 epidemic

  • The patient's state of health is compatible with the programme: psychological care for 6 months.

  • Information note signed by the patient

  • Any associated geographical, social or psychopathological conditions that might compromise the patient's ability to participate in the study

Exclusion Criteria:
  • Patient with no symptoms suggestive of moderate or high post-traumatic stress (IES-R score <24)

  • Patient deprived of liberty or under guardianship

  • Patient already receiving psychological care

  • Patient whose diagnosis of the disease was made within one month prior to the proposal for participation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Francois Baclesse Caen France

Sponsors and Collaborators

  • Centre Francois Baclesse

Investigators

  • Principal Investigator: Antony NARAYANASSAMY, M, Centre François Baclesse

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Francois Baclesse
ClinicalTrials.gov Identifier:
NCT04747249
Other Study ID Numbers:
  • 2020-A03234-35
First Posted:
Feb 10, 2021
Last Update Posted:
Apr 14, 2022
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 14, 2022